Gene editing is important for the development of highly productive, disease-resistant animals in agriculture, for the generation of scientific model organisms, and for biomedical research purposes. CRISPR-Cas9 editing processes involve DNA sequence modifications to targeted sites of the genome and can be used to silence undesirable traits in different organisms. Although there were concerns over off-target mutations involved in some of its earlier applications, the Type II CRISPR-Cas9 system has been demonstrated to produce mutations only at the targeted genomic site without inducing mutations at other functional regions of the genome. The CRISPR-Cas9 system has been utilized in various food production applications and in a variety of biomedical research studies on animal subjects and is considered safe for use in plants, non-human animals and primates, as well as for the therapeutic study of human diseases.
Introduction
In agriculture, gene editing is important for the development of highly productive disease-resistant animals, as well as for the generation of scientific model organisms for research purposes [1] . Editing processes involve DNA sequence modifications, such as insertions and deletions, to targeted sites of the genome. Some common editing technologies include the zinc finger nuclease (ZFN) [2, 3] and transcription activator-like effector nuclease (TALEN) systems [4] [5] [6] , and now the modern Type II CRISPR-Cas9 system [7, 8] . ZFNs are restriction enzymes array is subject to transcription processing of pre-crRNA, the precursor transcript, to produce mature, small interfering crRNA. During the interference phase, the mature crRNA directs Cas enzymes to target and cleave specific homologous invading nucleic acids [22, 23] . In nature, these defense mechanisms allow prokaryotic organisms to target and silence invading DNA elements to protect their systems against future attacks. The three stages of immunity are believed to be associated with the many distinct Cas enzymes containing varying, individual functions.
CRISPR-Cas core
The CRISPR region is associated with a diverse array of Cas genes and enzymes [24] . The more common CRISPRassociated enzyme, Cas9, is an RNA-guided DNA endonuclease enzyme which cleaves near the center portion of a phosphodiester bond of the target DNA site, the restriction site. The DNA strand is unevenly cleaved, creating complementary, single-stranded sticky ends, which may be paired and re-joined by DNA ligase to connect to the phosphodiester bonds of the DNA fragments. There are roughly 93 known Cas protein families associated with the many CRISPR-Cas systems of the various prokaryotic organisms [24] . The Cas enzymes are categorized based on their sequence similarities. Eleven of the 35 families make up the Cas core, which consists of Cas protein families 1-11. The CRISPR-Cas systems are divided into Class I, which utilizes a multiple complex of discrete Cas proteins to degrade foreign nucleic acids, and Class II, which incorporates one large Cas protein for nucleic acid degradation.
Each Class consists of three types with 19 subtypes. Class 1 contains Type I, Type III and Type IV, and Class 2 consists of Type II, Type V and Type VI. Each type, and most subtypes, are regulated by a unique signature Cas gene. Cas1 and Cas2 are conserved proteins of the adaptation phase of the prokaryotic immune system and are universal across each type and subtype. Cas3, Cas9 and Cas10 are universal across each type.
Cas1 and Cas2 are involved in the adaptation process of CRISPR-Cas systems throughout the majority of prokaryotic organisms [25] . Cas1 is a metal-dependent integrase enzyme featuring an α-helical fold [26] . Cas1 has the ability to cleave linear single-stranded DNA, single-stranded RNA and short double-stranded DNA fragments, as well as branched DNA substrates [27] , assisting the Cas1 enzyme to mediate the insertion of new protospacers into the CRISPR array by targeted cleavage at specific sites [28, 29] . Cas1 forms a complex with Cas2 to generate unevenly cleaved double-stranded fragments of the CRISPR array near the leader repeat. Cleavage activity is followed by the rejoining of the 5'-end of the repeating strand to the 3'-end of the newly-incorporated protospacer sequence [25] . The Cas1-Cas2 complex undergoes a conformational change upon binding of the protospacer, creating a flat surface ranging from a Cas1 dimer across a Cas2 dimer and then making contact with a second Cas1 dimer. The short 23 base pair fragment is flanked by tyrosine-22 from the first and second Cas1 dimers, allowing for protospacer recognition [30, 31] . Stable integration of the protospacer requires a supercoiling of target DNA, and that the inserted protospacer sequence contains 3'-OH ends to allow for a nucleophilic attack on the minus strand of the first repeating sequence [29] . Cas1 may form interactions with exonuclease enzymes recB, recC and RuvB, suggesting that Cas1 may play a dual role in DNA repair mechanisms [27] . The role of Cas2 is less understood in comparison to Cas1. Cas2 is a homologue of the mRNA interferase toxins [32] [33] [34] [35] , and the active mutant site of the J Bioinform Syst Biol 2019; 2 (2): 019-027 DOI: 10.26502/jbsb.5107005
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Cas2 enzyme has been shown to acquire new protospacers [31] . However, although Cas2 is a major portion of the Cas1-Cas2 complex, Cas2 may not be required for enzymatic activity and does not influence intrinsic sequence specificity [28, 35] . 
TYPE II CRISPR-Cas9 System
The more popular Type II CRISPR-Cas9 system is based on the Cas9 enzymes of prokaryotic organisms such as S.
pyogenes and S. aureus. The Type II system is beneficial for scientific research due to the Cas9 enzyme's ability to cleave nearly any sequence complementary to a sgRNA strand. The Type II system has been successfully applied across a variety of disciplines from genomic regulation to epigenome engineering, and ranging in areas from agriculture to gene therapy applications [37] . Genomic editing with CRISPR-Cas9 technology can be accomplished with the utilization of a viral vector system to target PGCs or somatic cell lines and introduce exogenous genes into the organism, which could produce gene-edited transgenic animals [38] .
CRISPR-Cas in Science
Although there were concerns over off-target mutations involved in some of its earlier applications [39] [40] [41] , the Type II CRISPR-Cas9 system has been demonstrated to produce mutations only at targeted genomic sites without inducing mutations at other functional regions of the genome [42] . The CRISPR-Cas9 system has been utilized in various food production applications and in a variety of biomedical research studies on animal subjects and is considered safe for use in plants [43] [44] [45] , non-human animals [46] and primates, as well as for the therapeutic study of human diseases. Some of its most significant contributions to biomedical research include the use of CRISPR-Cas9 to correct genetic mutations in skeletal muscle cells of mdx mouse models expressing Duchenne muscular dystrophy [47] , as well as a study in rhesus monkeys, which could ultimately lead to translational research in humans [42] ; the excision of the proviral genome HIV-1 from infected cells, which could provide a cure for HIVinfected patients [48] ; genome editing of myosin binding protein C3 (MYBPC3) mutations for the treatment of hypertrophic cardiomyopathy [49] ; and knockout of integrin α5 (ITGA5) from triple negative breast cancer cells for the treatment of metastatic triple negative breast cancer [50] . With the assistance of a modified CRISPR-Cas9 vector system, a research team at Vanderbilt University Medical Center demonstrated that particular single nucleotide polymorphisms (SNPs) associated with the expression of mouse Arntl2, a gene that encodes a circadian rhythm transcription factor, had a protective effect on the production of metastatic lesions in mouse models. In human breast cancer cases, those SNPs were associated with disease-free survival [51] . stem cells. The researchers concluded that genome editing induces a p53 and TP53 response, resulting in the toxicity [53] . Both groups advised that transfected cells should be monitored for p53 function [52, 53] . Another recent study revealed that CRISPR-Cas9 editing induced extensive damage from on-target copy number variations, including large deletions, insertions and inversions [54] .
CRISPR-Cas9 Toxicity
In addition to concerns over off-target mutations, another concern is the potentially harmful mutations that could be introduced through the disease-repair process, which could mediate repair in all cells, even in healthy ones [55] , as well as the risk of human embryonic germline modifications on future generations [56] . There are additional concerns that CRISPR-Cas9 could potentially be exploited for non-therapeutic uses, such as for the editing of human embryos for the purpose of creating "designer babies" [56, 57] .
Conclusions
Additional considerations involve changes made to an organism's metabolism, growth rate and response to environmental factors, which could have detrimental impacts on the surrounding environment. According to the USDA website, Congress has set up regulations to ensure the safety of genetically modified products based on the characteristics of the product and its intended use. The Food and Drug Administration, Animal and Plant Health Inspection Service and the Environmental Protection Agency oversee that all genetically modified products are safe for consumer use, safe for the environment and safe for use by farmers [58] . While the safety of human genome editing has not been yet been fully established [55] , if ultimately proven to be safe, CRISPR-Cas9 protocols could be used in future studies to treat various genetic conditions [59] .
